Skip to main content

4D Molecular Therapeutics, Inc. (FDMT)

NASDAQ: FDMT · IEX Real-Time Price · USD
35.18 -0.86 (-2.39%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap949.45M
Revenue (ttm)23.02M
Net Income (ttm)n/a
Shares Out26.99M
EPS (ttm)-3.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume102,975
Open35.47
Previous Close36.04
Day's Range34.70 - 36.04
52-Week Range21.40 - 55.11
Betan/a
Analystsn/a
Price Target50.00 (+42.1%)
Est. Earnings DateNov 11, 2021

About FDMT

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is ...

IndustryBiotechnology
IPO DateDec 11, 2020
Employees104
Stock ExchangeNASDAQ
Ticker SymbolFDMT
Full Company Profile

Financial Performance

In 2020, FDMT's revenue was $13.61 million, an increase of 94.85% compared to the previous year's $6.99 million. Losses were -$56.69 million, 15.0% more than in 2019.

Financial Statements

News

4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Me...

EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therap...

1 day ago - GlobeNewsWire

4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights

EMERYVILLE, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...

1 month ago - GlobeNewsWire

New Strong Sell Stocks for July 23rd

FDMT, BOOM, FRPT, GEL and HTBK have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2021.

Other symbols:BOOMFRPTGELHTBK
2 months ago - Zacks Investment Research

4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial ...

EMERYVILLE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...

3 months ago - GlobeNewsWire

4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights

EMERYVILLE, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapie...

4 months ago - GlobeNewsWire

4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for we...

EMERYVILLE, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapie...

4 months ago - GlobeNewsWire

4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berk...

EMERYVILLE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapie...

4 months ago - GlobeNewsWire

4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference

EMERYVILLE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therap...

4 months ago - GlobeNewsWire

4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-O...

- Abstracts on 4D-150 for wet AMD/DME and 4D-310 for Fabry disease accepted for oral presentations at ASGCT 24 th Annual Meeting

4 months ago - GlobeNewsWire

4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Hig...

- First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease

6 months ago - GlobeNewsWire

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fa...

EMERYVILLE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: 4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therap...

6 months ago - GlobeNewsWire

Andreas Halvorsen Jumps Into 2 New Biotech Companies

Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Picks, a Pre...

Other symbols:ABCL
9 months ago - GuruFocus

4D Molecular Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to P...

EMERYVILLE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power...

9 months ago - GlobeNewswire

4D Molecular Therapeutics Announces Upsized Pricing of Initial Public Offering Nasdaq:FMDT

EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power...

9 months ago - GlobeNewswire

Gene therapy developer 4D Molecular Therapeutics increases deal size by 58% ahead of $158 million IPO

4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised the proposed deal size for its upcoming IPO on Thursday. The Emeryville, CA-based compan...

9 months ago - NASDAQ

It's in the genes: Gene therapy developer 4D Molecular Therapeutics refiles for a $75 million IPO

4D Molecular Therapeutics, which is developing targeted gene therapies for multiple diseases, filed on Tuesday with the SEC to raise up to $75 million in an initial public offering.

10 months ago - NASDAQ

4D Molecular Therapeutics IPO Registration Document (S-1)

4D Molecular Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

10 months ago - SEC